Tal Zaks

10.4k total citations · 5 hit papers
51 papers, 6.9k citations indexed

About

Tal Zaks is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tal Zaks has authored 51 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 17 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tal Zaks's work include Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (11 papers) and Immunotherapy and Immune Responses (10 papers). Tal Zaks is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (11 papers) and Immunotherapy and Immune Responses (10 papers). Tal Zaks collaborates with scholars based in United States, United Kingdom and Israel. Tal Zaks's co-authors include Róbert Langer, Xucheng Hou, Yizhou Dong, Steven A. Rosenberg, Nicholas P. Restifo, Michael Watson, James D. Thompson, Mike Smith, Giuseppe Ciaramella and Örn Almarsson and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Tal Zaks

50 papers receiving 6.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lipid nanoparticles for mRNA delivery

2021 2.4k citations Tal Zaks et al. profile →
Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects

2004 626 citations David A. Tuveson, Alice T. Shaw et al. Cancer Cell profile →
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

2017 493 citations Kapil Bahl, Olga Yuzhakov et al. Molecular Therapy profile →
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

2019 331 citations Robert Feldman, Rainard Fuhr et al. Vaccine profile →
mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

2020 313 citations Tal Zaks, Steven A. Rosenberg et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tal Zaks United States	27	4.2k	1.9k	1.8k	1.2k	748	51	6.9k
Hugues Lortat‐Jacob France	53	3.8k 0.9×	2.1k 1.1×	1.3k 0.7×	637 0.5×	689 0.9×	146	8.1k
Mark C. Poznansky United States	35	1.7k 0.4×	2.2k 1.2×	1.8k 1.0×	1.8k 1.5×	463 0.6×	111	6.6k
Christof R. Hauck Germany	41	3.7k 0.9×	1.5k 0.8×	1.5k 0.8×	507 0.4×	427 0.6×	93	8.1k
Luigi Buonaguro Italy	49	3.2k 0.8×	2.4k 1.3×	2.1k 1.1×	1.2k 1.0×	569 0.8×	235	8.5k
Marco Rusnati Italy	55	5.8k 1.4×	1.7k 0.9×	996 0.5×	387 0.3×	660 0.9×	174	9.0k
Ying K. Tam United States	45	6.5k 1.6×	2.5k 1.3×	894 0.5×	1.8k 1.5×	1.2k 1.6×	107	9.3k
Marion Subklewe Germany	42	2.6k 0.6×	3.9k 2.1×	3.8k 2.1×	660 0.6×	687 0.9×	167	8.4k
Heidi Stuhlmann United States	34	3.8k 0.9×	1.7k 0.9×	732 0.4×	906 0.8×	1.3k 1.7×	71	7.1k
Elizabeth J. Read United States	34	1.5k 0.4×	2.9k 1.6×	1.4k 0.8×	1.3k 1.1×	665 0.9×	66	7.7k

Countries citing papers authored by Tal Zaks

Since Specialization

Citations

This map shows the geographic impact of Tal Zaks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tal Zaks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tal Zaks more than expected).

Fields of papers citing papers by Tal Zaks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tal Zaks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tal Zaks. The network helps show where Tal Zaks may publish in the future.

Co-authorship network of co-authors of Tal Zaks

This figure shows the co-authorship network connecting the top 25 collaborators of Tal Zaks. A scholar is included among the top collaborators of Tal Zaks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tal Zaks. Tal Zaks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

August, Allison, et al.. (2022). Clinical Development of mRNA Vaccines: Challenges and Opportunities. Current topics in microbiology and immunology. 440. 167–186. 8 indexed citations

August, Allison, Husain Attarwala, Sunny Himansu, et al.. (2021). A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nature Medicine. 27(12). 2224–2233. 118 indexed citations

Aliprantis, Antonios O., Christine A. Shaw, Paul Griffin, et al.. (2020). A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Human Vaccines & Immunotherapeutics. 17(5). 1248–1261. 111 indexed citations

Feldman, Robert, Rainard Fuhr, Igor Smolenov, et al.. (2019). mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 37(25). 3326–3334. 331 indexed citations breakdown →

Bahl, Kapil, Olga Yuzhakov, Alex Bulychev, et al.. (2017). Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Molecular Therapy. 25(6). 1316–1327. 493 indexed citations breakdown →

Galsky, Matthew D., Daniel D. Von Hoff, Marcus A. Neubauer, et al.. (2010). Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Investigational New Drugs. 30(2). 695–701. 52 indexed citations

Qian, Fawn, Stefan Engst, Toshihiro Yamaguchi, et al.. (2009). Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases. Cancer Research. 69(20). 8009–8016. 282 indexed citations

Greshock, Joel, Katherine L. Nathanson, Maria R. Ward, et al.. (2009). Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma‐derived cell lines. Genes Chromosomes and Cancer. 48(5). 419–428. 21 indexed citations

Greshock, Joel, Jie Cheng, David W. Rusnak, et al.. (2008). Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines. Molecular Cancer Therapeutics. 7(4). 935–943. 18 indexed citations

10.

Johnston, Stephen, Maureen Trudeau, Bella Kaufman, et al.. (2008). Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy. Journal of Clinical Oncology. 26(7). 1066–1072. 152 indexed citations

11.

Altorki, Nasser K., Michael J. Guarino, Harvey I. Pass, et al.. (2008). Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study. Journal of Clinical Oncology. 26(15_suppl). 7557–7557. 28 indexed citations

12.

Greshock, Joel, Katherine L. Nathanson, Anne‐Marie Martin, et al.. (2007). Cancer Cell Lines as Genetic Models of Their Parent Histology: Analyses Based on Array Comparative Genomic Hybridization. Cancer Research. 67(8). 3594–3600. 56 indexed citations

13.

Degenhardt, Yan, Katja Remlinger, Joel Greshock, et al.. (2006). Biomarker analyses of PLK isoforms in breast cancer. Cancer Research. 66. 459–459. 1 indexed citations

14.

Naylor, Tara L., Joel Greshock, Yan Wang, et al.. (2005). High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Research. 7(6). R1186–98. 165 indexed citations

15.

Tuveson, David A., Alice T. Shaw, Nicholas A. Willis, et al.. (2004). Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 5(4). 375–387. 626 indexed citations breakdown →

16.

Zaks‐Zilberman, Meirav, Tal Zaks, & Stefanie N. Vogel. (2001). INDUCTION OF PROINFLAMMATORY AND CHEMOKINE GENES BY LIPOPOLYSACCHARIDE AND PACLITAXEL (Taxol™) IN MURINE AND HUMAN BREAST CANCER CELL LINES. Cytokine. 15(3). 156–165. 88 indexed citations

17.

Karas, Michael, Tal Zaks, Shoshana Yakar, Mark E. Dudley, & Derek LeRoith. (2001). TCR stimulation protects CD8+ T cells from CD95 mediated apoptosis. Human Immunology. 62(1). 32–38. 12 indexed citations

18.

Karas, Michael, Tal Zaks, Jun‐Li Liu, & Derek LeRoith. (1999). T Cell Receptor-induced Activation and Apoptosis In Cycling Human T Cells Occur throughout the Cell Cycle. Molecular Biology of the Cell. 10(12). 4441–4450. 18 indexed citations

19.

Han, Ying, Tal Zaks, Rong‐Fu Wang, et al.. (1999). Cancer therapy using a self-replicating RNA vaccine. Nature Medicine. 5(7). 823–827. 269 indexed citations

20.

Zaks, Tal & Steven A. Rosenberg. (1998). Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.. PubMed. 58(21). 4902–8. 188 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact